PI3K signaling maintains c‐myc expression to regulate transcription of E2F1 in pancreatic cancer cells

Phosphatidylinositol 3‐kinase (PI3K) signaling controls survival and proliferation of cancer cells and is activated in around 60% of pancreatic ductal adenocarcinomas (PDACs). Although not entirely clarified, PI3K signaling is linked to cell cycle progression of PDAC cells. In this study we demonstrate that PI3K signaling controls transcription of the E2F1 gene and show that E2F1 is essential for S‐phase progression of PDAC cells. On the molecular level, PI3K signaling controls c‐myc protein abundance in a glycogen synthase kinase‐3 (GSK3)‐dependent fashion. c‐myc binds to the E‐box of the E2F1 gene in PDAC cells and this binding is under control of the PI3K‐signaling pathway. Together, we demonstrate that PI3K–GSK3‐dependent control of c‐myc protein expression is connected to the transcription of the E2F1 gene in PDAC cells, leading to S‐phase progression of the cell cycle. © 2009 Wiley‐Liss, Inc.

[1]  L. Penn,et al.  Reflecting on 25 years with MYC , 2008, Nature Reviews Cancer.

[2]  D. Ginsberg,et al.  E2F - at the crossroads of life and death. , 2008, Trends in cell biology.

[3]  R. Eisenman,et al.  Myc's broad reach. , 2008, Genes & development.

[4]  S. Thorgeirsson,et al.  E2F1 inhibits c-Myc-driven apoptosis via PIK3CA/Akt/mTOR and COX-2 in a mouse model of human liver cancer. , 2008, Gastroenterology.

[5]  A. Baldwin,et al.  Maintenance of constitutive IkappaB kinase activity by glycogen synthase kinase-3alpha/beta in pancreatic cancer. , 2008, Cancer research.

[6]  D. Cunningham,et al.  Survival from cancer of the pancreas in England and Wales up to 2001 , 2008, British Journal of Cancer.

[7]  L. Zhao,et al.  Class I PI3K in oncogenic cellular transformation , 2008, Oncogene.

[8]  S. Pastorino,et al.  Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-kappaB, and glucose regulation. , 2008, Cancer research.

[9]  Z. Wang,et al.  Pim kinase-dependent inhibition of c-Myc degradation , 2008, Oncogene.

[10]  Paul Workman,et al.  Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. , 2008, Current opinion in pharmacology.

[11]  J. Nevins,et al.  A role for Myc in facilitating transcription activation by E2F1 , 2008, Oncogene.

[12]  Seiichi Mori,et al.  An E2F1-dependent gene expression program that determines the balance between proliferation and cell death. , 2008, Cancer cell.

[13]  Joerg Schwock,et al.  Immunohistochemical analysis of changes in signaling pathway activation downstream of growth factor receptors in pancreatic duct cell carcinogenesis , 2008, BMC Cancer.

[14]  E. Brambilla,et al.  E2F-1, Skp2 and cyclin E oncoproteins are upregulated and directly correlated in high-grade neuroendocrine lung tumors , 2007, Oncogene.

[15]  J. Partanen,et al.  c-Myc Blazing a Trail of Death: Coupling of the Mitochondrial and Death Receptor Apoptosis Pathways by c-Myc , 2007, Cell cycle.

[16]  D. Saur,et al.  HDAC3 is linked to cell cycle machinery in MiaPaCa2 cells by regulating transcription of skp2 , 2007, Cell proliferation.

[17]  D. Saur,et al.  Phosphoinositide-3-kinase signaling controls S-phase kinase-associated protein 2 transcription via E2F1 in pancreatic ductal adenocarcinoma cells. , 2007, Cancer research.

[18]  B. Yung,et al.  Nucleophosmin/B23 regulates transcriptional activation of E2F1 via modulating the promoter binding of NF-kappaB, E2F1 and pRB. , 2006, Cellular signalling.

[19]  T. Smyrk,et al.  Aberrant Nuclear Accumulation of Glycogen Synthase Kinase-3β in Human Pancreatic Cancer: Association with Kinase Activity and Tumor Dedifferentiation , 2006, Clinical Cancer Research.

[20]  D. Saur,et al.  IKKα controls p52/RelB at the skp2 gene promoter to regulate G1‐ to S‐phase progression , 2006, The EMBO journal.

[21]  T. Gress,et al.  Overexpression of c‐myc in pancreatic cancer caused by ectopic activation of NFATc1 and the Ca2+/calcineurin signaling pathway , 2006, The EMBO journal.

[22]  Ji Luo,et al.  The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism , 2006, Nature Reviews Genetics.

[23]  Robbie Loewith,et al.  A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling , 2006, Cell.

[24]  C. Wang,et al.  F-box protein Skp2: a novel transcriptional target of E2F , 2006, Oncogene.

[25]  Anna M. Heidenblut,et al.  Transcriptome analysis of microdissected pancreatic intraepithelial neoplastic lesions , 2005, Oncogene.

[26]  R. Schmid,et al.  Pancreatic cancer: basic and clinical aspects. , 2005, Gastroenterology.

[27]  Zhimin Wei,et al.  Beta-catenin up-regulates the expression of cyclinD1, c-myc and MMP-7 in human pancreatic cancer: relationships with carcinogenesis and metastasis. , 2005, World journal of gastroenterology.

[28]  R. Urrutia,et al.  Glycogen Synthase Kinase-3β Participates in Nuclear Factor κB–Mediated Gene Transcription and Cell Survival in Pancreatic Cancer Cells , 2005 .

[29]  R. Urrutia,et al.  Glycogen synthase kinase-3beta participates in nuclear factor kappaB-mediated gene transcription and cell survival in pancreatic cancer cells. , 2005, Cancer research.

[30]  D. Ginsberg,et al.  Transcriptional regulation of AKT activation by E2F. , 2004, Molecular cell.

[31]  Yixin Yao,et al.  The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-κB and c-Myc in pancreatic cancer cells , 2004, Oncogene.

[32]  R. Jope,et al.  The glamour and gloom of glycogen synthase kinase-3. , 2004, Trends in biochemical sciences.

[33]  L. Beckett,et al.  Incidence, mechanism and prognostic value of activated AKT in pancreas cancer , 2003, British Journal of Cancer.

[34]  John S Lazo,et al.  Low molecular weight inhibitors of Myc–Max interaction and function , 2003, Oncogene.

[35]  J. Nevins,et al.  Specificity in the activation and control of transcription factor E2F-dependent apoptosis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[36]  Rork Kuick,et al.  Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. , 2003, Cancer research.

[37]  Andrea Cocito,et al.  Genomic targets of the human c-Myc protein. , 2003, Genes & development.

[38]  F. Kondo,et al.  Expression of transcription factor E2F-1 in pancreatic ductal carcinoma: an immunohistochemical study. , 2003, Pathology, research and practice.

[39]  Mattias Höglund,et al.  Frequent amplification of 8q24, 11q, 17q, and 20q‐specific genes in pancreatic cancer , 2002, Genes, chromosomes & cancer.

[40]  H. Zentgraf,et al.  c-MYC Activation in Primary and Metastatic Ductal Adenocarcinoma of the Pancreas: Incidence, Mechanisms, and Clinical Significance , 2002, Modern Pathology.

[41]  B. Pützer,et al.  Therapeutic efficacy of E2F1 in pancreatic cancer correlates with TP73 induction. , 2001, Cancer research.

[42]  Y Taya,et al.  Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. , 2000, Genes & development.

[43]  J. Woodgett,et al.  Requirement for glycogen synthase kinase-3β in cell survival and NF-κB activation , 2000, Nature.

[44]  J. Woodgett,et al.  Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. , 2000, Nature.

[45]  G. Cooper,et al.  Role of Glycogen Synthase Kinase-3 in the Phosphatidylinositol 3-Kinase/Akt Cell Survival Pathway* , 1998, The Journal of Biological Chemistry.

[46]  Joseph R. Nevins,et al.  Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F , 1997, Nature.

[47]  P. Cohen,et al.  Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B , 1995, Nature.

[48]  J. Woodgett,et al.  Site-specific modulation of c-Myc cotransformation by residues phosphorylated in vivo. , 1994, Oncogene.

[49]  R. Palmiter,et al.  Pancreatic tumor pathogenesis reflects the causative genetic lesion. , 1991, Proceedings of the National Academy of Sciences of the United States of America.